Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Myeloproliferative neoplasms and pregnancy: Overview and practice recommendations.

American journal of hematology - 1 Mar 2021

Gangat Naseema, Tefferi Ayalew

Abstract excerpt

Pregnancy in the context of myeloproliferative neoplasms (MPN) poses unique fetal and maternal challenges. Current literature in this regard mostly involves essential thrombocythemia (ET) and less so polycythemia vera (PV) or myelofibrosis. In ET, live birth rate is estimated at 70% with first trimester fetal loss (˜ 30%) as the major complication. Risk of pregnancy-associated complications is higher in PV, thus...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Abortion, Spontaneous
Share to Infant, Low Birth Weight
Share to Live Birth

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Multicenter Studies as Topic

Share to Phlebotomy

Share to Pregnancy Complications, Neoplastic

Share to Prenatal Care

Share to Puerperal Disorders

Source

Identifiers

PMID: 33296529
DOI: 10.1002/ajh.26067

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Myeloproliferative neoplasms and pregnancy: Overview and practice recommendations.PMID 33296529Read ↗

How we manage Philadelphia‐negative myeloproliferative neoplasms in pregnancySemantic proximity Read ↗

Topics of Interest in Women With Myeloproliferative Neoplasms.Semantic proximity Read ↗

Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management.Semantic proximity Read ↗

Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk-stratification, and management.Semantic proximity Read ↗

Prognostic risk model for patients with high-risk polycythemia vera and essential thrombocythemia.Semantic proximity Read ↗

Austrian recommendations for the management of essential thrombocythemia.Semantic proximity Read ↗

Evidence and expertise in the management of polycythemia vera and essential thrombocythemia.Semantic proximity Read ↗

Thrombotic and bleeding complications in classical myeloproliferative neoplasms.Semantic proximity Read ↗

Thrombosis-Driven Disease Progression in JAK2-Mutant Polycythemia Vera and Essential Thrombocythemia: Reassessing Risk-Based Management.Semantic proximity Read ↗

Essential thrombocythaemia: A contemporary approach with new drugs on the horizon.Semantic proximity Read ↗

Outcomes of the Pregnancies with Chronic Myeloid Leukemia in the Tyrosine Kinase Inhibitor Era and Literature ReviewSemantic proximity Read ↗

Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk-stratification and management.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.